E-LIB Suche - Ergebnisse für: Scherer, Josef

1

Das Masterprogramm "Risiko- und Compliance-Management" - ei..:

, In: Betriebswirtschaftliches Risikomanagement im Krankenhaus / Wolfgang Hellmann, Karl Ehrenbaum, Frank Meyer, Ingo Kutschka

Scherer, Josef ; Brunner, Corina. (2020) - p. 199-202

Copies: Zentrale:E02 a vwl 296.7/867; TB BHV: mmt 980/30

2

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virolo..:

Cooper, David A. ; Cordery, Damien V. ; Zajdenverg, Roberto...
PLOS ONE. 11 (2016) 1 - p. e0144917 , 2016

Link: https://doi.org/10.1371/..

3

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymer..:

Berger, Kristi L. ; Sarrazin, Christoph ; Nelson, David R....
PLOS ONE. 11 (2016) 8 - p. e0160668 , 2016

Link: https://doi.org/10.1371/..

4

Faldaprevir, pegylated interferon, and ribavirin for treatm..:

Jensen, Donald M. ; Asselah, Tarik ; Dieterich, Douglas...
Annals of Hepatology. 15 (2016) 3 - p. 333-349 , 2016

Link: https://doi.org/10.5604/..

5

Safety and efficacy of faldaprevir in combination with pegy..:

Nishiguchi, Shuhei ; Urano, Yasuhisa ; Suzaki, Keiko...
Hepatology Research. 47 (2016) 3 - p. E142-E151 , 2016

Link: https://doi.org/10.1111/..

6

STARTVerso1: A randomized trial of faldaprevir plus pegylat..:

Ferenci, Peter ; Asselah, Tarik ; Foster, Graham R....
Journal of Hepatology. 62 (2015) 6 - p. 1246-1255 , 2015

Link: https://doi.org/10.1016/..

7

Rechtlicher Rahmen für das Logistik-(Risiko-)Management:

, In: Risikomanagement in der Logistik,

Scherer, Josef - p. 171-208 , 2015

Link: https://doi.org/10.1007/..

8

240 Similar Adjusted Svr12 Rates for HIV Co-Infected and HC..:

Dieterich, Douglas T. ; Ferenci, Peter ; Jacobson, Ira M....
Gastroenterology. 146 (2014) 5 - p. S-905 , 2014

Link: https://doi.org/10.1016/..

9

Su1058 Early Stopping Rules for Faldaprevir Plus Pegylated ..:

Ferenci, Peter ; Dieterich, Douglas T. ; Zeuzem, Stefan...
Gastroenterology. 146 (2014) 5 - p. S-977 , 2014

Link: https://doi.org/10.1016/..

10

Su1049 Faldaprevir Plus Pegylated Interferon Alfa-2A and Ri..:

Jensen, Donald M. ; Foster, Graham ; Ferenci, Peter...
Gastroenterology. 146 (2014) 5 - p. S-974 , 2014

Link: https://doi.org/10.1016/..

11

Su1056 Effect of HCV Genotype-1 Subtype on Response to Fald..:

Jacobson, Ira M. ; Jensen, Donald M. ; Dieterich, Douglas T....
Gastroenterology. 146 (2014) 5 - p. S-976 , 2014

Link: https://doi.org/10.1016/..

12

Su1054 Ns3 Q80k Did Not Impact Efficacy or Treatment-Emerge..:

Berger, Kristi ; Sarrazin, Christoph ; Ferenci, Peter...
Gastroenterology. 146 (2014) 5 - p. S-976 , 2014

Link: https://doi.org/10.1016/..

13

Su1020 Faldaprevir Efficacy in HCV Genotype-1-Infected Pati..:

Berger, Kristi ; Sarrazin, Christoph ; Jacobson, Ira M....
Gastroenterology. 146 (2014) 5 - p. S-964 , 2014

Link: https://doi.org/10.1016/..

14

Structural Strengthening of Concrete with Fiber Reinforced ..:

Michels, Julien ; Zwicky, Daia ; Scherer, Josef..
Advances in Structural Engineering. 17 (2014) 12 - p. 1785-1799 , 2014

Link: https://doi.org/10.1260/..

15

Su1062 Comparisons of Populations in Faldaprevir Phase III ..:

Ferenci, Peter ; Jensen, Donald M. ; Dieterich, Douglas T....
Gastroenterology. 146 (2014) 5 - p. S-978 , 2014

Link: https://doi.org/10.1016/..